Senti Biosciences Holdings, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(16,971) | $(28,845) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 2,363 | 2,730 |
| Depreciation | 1,355 | 1,840 |
| Gain on lease modification | (6,762) | — |
| Gain on change in fair value of convertible notes - related party | (271) | — |
| Convertible note issuance costs included in net loss - related party | 300 | — |
| Other non-cash charges | 52 | 39 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 323 | (9) |
| GeneFab receivable - related party | 715 | (1,878) |
| GeneFab prepaid expenses - related party | (1,328) | 1,156 |
| Prepaid expenses and other assets | 619 | 614 |
| Operating lease right-of-use assets | 1,032 | 1,104 |
| Accounts payable | (670) | (180) |
| Accrued expenses and other current liabilities | (1,272) | (1,167) |
| Operating lease liabilities | (2,719) | (2,227) |
| GeneFab sublease deferred income - related party | 1,635 | (300) |
| Deferred revenue - related party | (32) | — |
| Other non-current liabilities | (99) | — |
| Net cash used in operating activities | (21,730) | (27,123) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Proceeds from sale of property and equipment | 114 | 12 |
| Purchases of property and equipment | — | (196) |
| Net cash provided by (used in) investing activities | 114 | (184) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from issuance of convertible notes - related party | 9,700 | — |
| Payment of issuance costs | (25) | (2,457) |
| Taxes paid related to net settlement of stock awards | (118) | — |
| Proceeds from CIRM Grant | — | 2,520 |
| Proceeds from issuance of common stock related to ATM, net of commissions | — | 534 |
| Net cash provided by financing activities | 9,557 | 597 |
| NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | (12,059) | (26,710) |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period | 19,948 | 51,815 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period | $7,889 | $25,105 |
| SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION: | ||
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Capital contribution from related party upon initial recognition of convertible notes at fair value - related party | $5,736 | $— |
| Unpaid issuance costs | $340 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.